Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb, Exelixis, Extend Oncology Research Collaboration

NEW YORK, Dec. 17 (GenomeWeb News) - Exelixis and Bristol-Myers Squibb Company have extended their oncology research collaboration until December 2006, the companies said today.

 

The collaboration, originally announced in July 2001, involves discovery of potential drug targets for cancer. Initially, Bristol-Myers made a $20 million equity investment in Exelixis, and a $5 million upfront payment for Exelixis' functional genomics services, followed by $3 million a year for at least three years.

 

Under this extended deal, the parties have the goal of increasing the number and degree of validation of cancer targets that will be delivered by Bristol-Myers Squibb. Each party will maintain the exclusive worldwide rights to equal numbers of validated targets that stem from the collaboration.

 

Bristol-Myers Squibb will make an an upfront payment to Exelixis, will increase its annual research funding, and will provide milestones on validated cancer targets. The company will also provide Exelixis milestone payments on compounds that go through regulatory and clinical stages.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.